Early screen for undiagnosed Type 2 DM. 2-step testing is common:

By rray, 28 November, 2014
Exclude Patient Type Detail Header
No
Footnote
<sup>1</sup> Select consistent cut-offs for practice, considering factors like community GDM prevalence, resource availability, etc. No RCTs support benefit for specific 1-h cut-off. For 3-h cut-off, no clear comparative trial results available; select either Carpenter/Coustan (140 mg/dL, plasma/serum) or NDDG (145 mg/dL plasma).<br><br><sup>2</sup> Insufficient evidence exists about optimal BG monitoring freq. No study has demonstrated superiority of 1- vs 2-h postprandial BG. ADA and ACOG recommend 140 mg/dL @ 1 h post prandial, or 120 mg/dL @ 2 h, to ↓ macrosomia risk.<br><br>
<sup>3</sup> Antepartum fetal testing is recommended if established pre-preg DM. There is no consensus regarding antepartum testing in well-controlled GDM; choose per local practice.
Detail Type
Text
Patient Type Detail Header (Long)
Early screen for undiagnosed Type 2 DM. 2-step testing is common: